Free Trial
NYSE:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$1.13 +0.24 (+27.54%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.12 -0.01 (-0.88%)
As of 08/8/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Matinas Biopharma Stock (NYSE:MTNB)

Key Stats

Today's Range
$0.89
$1.13
50-Day Range
$0.81
$1.13
52-Week Range
$0.47
$8.39
Volume
304,331 shs
Average Volume
296,062 shs
Market Capitalization
$5.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Matinas Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

MTNB MarketRank™: 

Matinas Biopharma scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Matinas Biopharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Matinas Biopharma is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Matinas Biopharma has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.82% of the float of Matinas Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas Biopharma has recently decreased by 41.81%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Matinas Biopharma does not currently pay a dividend.

  • Dividend Growth

    Matinas Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.82% of the float of Matinas Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas Biopharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas Biopharma has recently decreased by 41.81%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added Matinas Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Matinas Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 11.77% of the stock of Matinas Biopharma is held by institutions.

  • Read more about Matinas Biopharma's insider trading history.
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

MTNB Matinas BioPharma Holdings, Inc. - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) - Yahoo Finance
Your blueprint for crypto wealth
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
Matinas BioPharma files to sell 16.9M shares of common stock for holders
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $0.51 at the beginning of 2025. Since then, MTNB shares have increased by 121.6% and is now trading at $1.13.

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

Last Earnings
8/14/2024
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MTNB
Previous Symbol
NYSE:MTNB
CIK
1582554
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$22.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-123.06%
Return on Assets
-94.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.53
Quick Ratio
5.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.43 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
5,087,000
Free Float
4,599,000
Market Cap
$5.75 million
Optionable
N/A
Beta
1.32

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:MTNB) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners